Active hormone therapy, indeed, represents a significant risk factor of diabetes among breast cancer survivors [26], particularly aromatase inhibitors, which exert a powerful detrimental effect on insulin sensitivity and central adiposity [27]. The gene discussed is CYP19A1; the disease is breast carcinoma.